Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.

X
Trial Profile

An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fondaparinux sodium (Primary) ; Fondaparinux sodium (Primary) ; Heparin
  • Indications Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OASIS-6
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Mar 2020 Results examining whether machine learning could discover unknown associations from results of the OASIS-6 trial, in patients with ST-segment elevation myocardial infarctionpresented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 15 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top